Nexium (Esomeprazole)

Esomeprazole, the active ingredient in Nexium, is a proton pump inhibitor presented as an injection for intravenous use. It treats gastro‑oesophageal reflux disease, erosive oesophagitis and helps prevent NSAID‑induced gastric ulcers in adults.

GNH USA supplies Nexium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Esomeprazole acts on the gastric acid secretion pathway to manage acid‑related disorders.

- Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. - Erosive oesophagitis: promotes healing of acid‑induced esophageal lesions. - Prevention of NSAID‑induced gastric ulcers: decreases risk of ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs.

Common side effects are generally mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools occurring during treatment. - Nausea: feeling of queasiness. - Abdominal pain: discomfort in the stomach region.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis requiring medical attention. - Anaphylaxis: rapid onset of allergic reaction with breathing difficulty. - Hypomagnesemia: low serum magnesium levels, potentially causing muscle cramps or cardiac arrhythmia.

Before initiating therapy, consider the following precautions.

- Assess renal function: dose may need adjustment in severe renal impairment. - Monitor for infection: prolonged acid suppression can increase risk of gastrointestinal infections. - Check electrolytes: long‑term use may cause low magnesium or calcium. - Avoid concomitant use with certain drugs: consider interaction with antiplatelet agents. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Esomeprazole may interact with several medicines; categorize the risk level.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption of atazanavir. - High‑dose methotrexate: increased toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, monitor coagulation. - Digoxin: may raise serum levels, monitor for toxicity. - Diazepam: may increase plasma concentration, monitor sedation.